Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous versus oral cyclophosphamide in primary membranous nephropathy
IRCT20230517058211N1Phase 3Completed
- Sponsor
- Jinnah Hospital
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide in idiopathic membranous glomerulonephritis (IMG) (2 arms), sponsored by Jinnah Hospital. Primary endpoints: Spot urinary protein to creatinine ratio, Serum creatinine and 6 more. Started Jun 2023; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on IRCT20230517058211N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230517058211N1.